A detailed history of Marshall Wace, LLP transactions in Celcuity Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 11,877 shares of CELC stock, worth $148,106. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,877
Previous 152,291 92.2%
Holding current value
$148,106
Previous $2.49 Million 92.9%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$13.98 - $19.15 $1.96 Million - $2.69 Million
-140,414 Reduced 92.2%
11,877 $177,000
Q2 2024

Aug 14, 2024

BUY
$14.1 - $20.78 $613,011 - $903,431
43,476 Added 39.95%
152,291 $2.49 Million
Q1 2024

May 15, 2024

BUY
$13.74 - $21.6 $1.5 Million - $2.35 Million
108,815 New
108,815 $2.35 Million

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $186M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.